29EE Intenzo, Charles M. - Thomas Jefferson University - Thomas Jefferson University
cmi101

Charles Intenzo, MD

Contact Dr. Intenzo

132 South 10th Street
Suite 861, Main Building
Philadelphia, PA 19107

(215) 955-7871
(215) 923-0268 fax

Most Recent Peer-reviewed Publications

  1. N-Acetyl cysteine may support dopamine neurons in Parkinson's disease: Preliminary clinical and cell line data
  2. VPAC1 targeted 64Cu-TP3805 positron emission tomography imaging of prostate cancer: Preliminary evaluation in man
  3. Yttrium-90 microsphere brachytherapy for liver metastases from uveal melanoma clinical outcomes and the predictive value of fluorodeoxyglucose positron emission tomography
  4. Provider Distribution Changes in Dual-Energy X-Ray Absorptiometry in the Medicare Population Over the Past Decade
  5. <sup>90</sup>Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies
  6. Clinical comparison of99mTc exametazime and123I ioflupane SPECT in patients with chronic mild traumatic brain injury
  7. Effectiveness of PET/CT in the preoperative evaluation of neck disease
  8. Altered drainage patterns in patients with melanoma and previous axillary dissection
  9. VPAC1 receptors for imaging breast cancer: A feasibility study
  10. Somatostatin receptor scintigraphy in patients with metastatic uveal melanoma
  11. Recent reimbursement changes and their effect on hospital and private office use of myocardial perfusion imaging
  12. Value of fluoro-2-deoxy-D-glucose-positron emission tomography for detecting metastatic lesions in head and neck cancer
  13. SNM practice guideline for parathyroid scintigraphy 4.0
  14. Positron Emission Tomography for neck evaluation following definitive treatment with chemoradiotherapy for locoregionally advanced head and neck squamous cell carcinoma
  15. Imaging of the thyroid in benign and malignant disease
  16. Subclinical hyperthyroidism: Current concepts and scintigraphic imaging
  17. A phase i trial of samarium-153-lexidronam complex for treatment of clinically nonmetastatic high-risk prostate cancer: First report of a completed study
  18. FDG-PET staging and importance of lymph node SUV in head and neck cancer
  19. Lymphoscintigraphy in cutaneous melanoma: An updated total body atlas of sentinel node mapping
  20. Pretreatment FDG-PET standardized uptake value as a prognostic factor for outcome in head and neck cancer
0